Abstract:
:Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproliferations. Several signalling pathways, cell of origin of PTLD and their relation to viruses were analysed by immunohistochemistry and in situ hybridization. Most PTLD were of activated B-cell origin. Two-thirds of cases showed an Epstein-Barr virus (EBV) infection of the neoplastic cells. NF-κB signalling components were present in the majority of cases, except for EBV-infected cases with latency type III lacking CD19 and upstream B-cell signalling constituents. Proteins involved in B-cell receptor signalling like Bruton tyrosine kinase were only present in a minority of cases. Phosphoinositide 3-kinase (PI3K) was expressed in 94% of cases and the druggable PI3K class 1 catalytic subunit p110 in 76%, while proteins of other signalling transduction pathways were expressed only in single cases. Unsupervised cluster analysis revealed three distinct subgroups: (i) related to EBV infection, mainly latency type III and mostly lacking CD19, upstream B-cell signalling and NF-κB constituents; (ii) mostly related to EBV infection with expression of the alternative NF-κB pathway compound RelB, CD10, and FOXP1 or MUM1; and finally, (iii) mostly unrelated to virus infection with expression of the classic NF-κB pathway compound p65. EBV and NF-κB are important drivers in PTLD in contrast to B-cell receptor signalling. The main signal transduction pathway is related to PI3K. This links PTLD to other subgroups of EBV-related lymphomas, highlighting also new potential treatment approaches. Copyright © 2016 John Wiley & Sons, Ltd.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov Adoi
10.1002/hon.2280subject
Has Abstractpub_date
2017-06-01 00:00:00pages
187-197issue
2eissn
0278-0232issn
1099-1069journal_volume
35pub_type
杂志文章abstract::Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2016
更新日期:2013-03-01 00:00:00
abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070407
更新日期:1989-07-01 00:00:00
abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...
journal_title:Hematological oncology
pub_type:
doi:10.1002/hon.2376
更新日期:2017-12-01 00:00:00
abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2775
更新日期:2020-10-01 00:00:00
abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2192
更新日期:2016-06-01 00:00:00
abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.822
更新日期:2007-09-01 00:00:00
abstract::The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900110207
更新日期:1993-03-01 00:00:00
abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2676
更新日期:2020-02-01 00:00:00
abstract::Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2772
更新日期:2020-10-01 00:00:00
abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64
更新日期:1999-12-01 00:00:00
abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2515
更新日期:2018-10-01 00:00:00
abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2035
更新日期:2013-09-01 00:00:00
abstract::The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2423
更新日期:2018-02-01 00:00:00
abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2522
更新日期:2018-12-01 00:00:00
abstract::Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070210
更新日期:1989-03-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.1017
更新日期:2012-09-01 00:00:00
abstract::Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900090608
更新日期:1991-11-01 00:00:00
abstract::Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.858
更新日期:2008-09-01 00:00:00
abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2368
更新日期:2017-12-01 00:00:00
abstract::The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900040403
更新日期:1986-10-01 00:00:00
abstract::Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffus...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.791
更新日期:2006-12-01 00:00:00
abstract::A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070503
更新日期:1989-09-01 00:00:00
abstract::This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.860
更新日期:2008-12-01 00:00:00
abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2116
更新日期:2014-09-01 00:00:00
abstract::Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100303
更新日期:1992-05-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.792
更新日期:2006-12-01 00:00:00
abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2647
更新日期:2019-10-01 00:00:00
abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.714
更新日期:2003-09-01 00:00:00
abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2279
更新日期:2017-09-01 00:00:00